Скачать или смотреть Finding Funding during the SBIR Lapse

SBIR reauthorization isn’t guaranteed — and waiting could cost you funding.

In this video, we break down what SBIR reauthorization really means for biotech and medtech companies, what happens if it lapses, and how to position your company to win funding with or without reauthorization.

Whether you're targeting NIH, NSF, DoD, AFWERX, ARPA-H, or other federal agencies, preparation — not waiting — is what separates funded companies from everyone else.

In this video, you’ll learn:

• What SBIR reauthorization actually impacts
• What stops vs. what continues during a lapse
• What agencies do when reauthorization passes
• How to prepare during the waiting period
• Alternative non-dilutive funding options beyond SBIR
• How to build a grant strategy that works in any scenario

Reauthorization can create compressed timelines, higher competition, and overwhelmed program officers — but if you're ready, you gain a major advantage.

Don’t just wait — prepare.

Who This Is For:

Biotech founders

Medtech startups

Small businesses pursuing SBIR/STTR

First-time federal grant applicants

Companies seeking non-dilutive funding

Work With BW&CO

We help biotech and medtech companies secure federal funding through strategic positioning, proposal development, and agency alignment.

Learn more:
🌐 www.bwcoconsulting.com